natgillin/translations-raw huggingface dataset:
A T-cell receptor (TCR) which recognises a cell which aberrantly expresses a polypeptide comprising an amino acid sequence given in any one of Claims 1 to 3, or the TCR being obtainable from the cytotoxic T lymphocyte (CTL) of Claim 19. A nucleic acid encoding a T-cell receptor (TCR) according to Claim 20. An expression vector capable of expressing a T-cell receptor (TCR) according to Claim 20. 
Receptor T stanica (TCR) koji prepoznaje stanicu koja abnormalno eksprimira polipeptid sastavljen od aminokiselinskog slijeda spomenutog u bilo kojem od Zahtjeva 1 ili 2, pri čemu je TCR specifičan za peptide iz bilo kojeg Zahtjeva od 1 ili 2 te se može dobiti od citotoksičnih limfocita (CTL-a) iz Zahtjeva 16. Nukleinska kiselina koja kodira receptor T stanica (TCR) prema Zahtjevu 17 ili vektor ekspresije sposoban za ekspresiju spomenutog receptora T stanice (TCR).
In case a generation of a new key is initiated by the second integrated device, i.e. the device that keeps the secret data, the active key is replaced by the new generated key at both side of the communication link, that is to say at the first and second circuitry. 
- sredstvo za pokretanje i obrada generiranja novog sigurnosnog ključa nakon uključivanja, radi zamjene aktivnog sigurnosnog ključa u prvom i drugom integriranom krugu (10, 20), gdje prvi integrirani krug (10) sadrži:
blending said granulated mixture with at least one bioadhesive polymer, at least one sustained release polymer and at least one compression agent; and compressing the blended mixture obtained in b). 
€) miješanje navedenih primarnih granula sa najmanje jednim bioadhezivnim polimerom i najmanje jednim polimerom za produženo oslobađanje i najmanje jednim sredstvom za prešanje; i f) prešanje navedene smjese u e).
Soc., 109, 5544 (1987) and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. 
Soc, 109, 5544 (1987) i ciklopropani, kao što je izvjestio Capson, T.L., PhD dizertacija.
The glass fiber product of claim 16, wherein said thermally curable aqueous binder composition is thermally curable to a thermoset polyester resin. 
Proizvod od staklenih vlakana prema zahtjevu 30, gdje se vodena smjesa veziva koja se može termički stvrdnuti, termički učvršćuje za poliestersku smolu koja je termički očvrsnuta.
An effective amount of a compound of any one of claims 1-6 or a composition of claim 7 for use in the treatment of cancer, preferably, the cancer is pancreatic cancer, prostate cancer, lung cancer, melanoma, breast cancer, colon cancer, or ovarian cancer. 
Spoj ili farmaceutski pripravak za primjenu sukladno zahtjevu 8,, naznačen time, da je rak rak pankreasa, rak prostate, rak pluća, melanom, rak dojke, rak debelog crijeva, ili karcinom jajnika.
a polyol component which is a polycarbonate diol prepared from 1,6-hexanediol and dimethyl carbonate, wherein said polycarbonate diol has a number average molecular weight of from 1000 to 2500 g/mol, 
komponenta poliola koja je polikarbonatni diol proizveden od 1,6-heksandiola i dimetil karbonata, pri čemu navedeni polikarbonatni diol ima brojčani prosjek molekulske mase od 1000 do 2500 g/mol,
subjecting the membrane effluent comprising the polypeptide of interest to a anion exchange chromatography purification step, and 
podvrgavanja efluenta membrane koji sadrži željeno protutijelo koraku pročišćavanja kromatografijom anionske izmjene, te
An additional foil disk with a 0.049 in. (1.24 mm) central hole as inserted into the foil tube on the mouth end of the tobacco. 
Dopunski disk od folije 3a centralnim otvorom od 1.24 mm umetne se u cijev sa folijom na usnom kraju duhana.
The composition or vaccine for use of claim 13 wherein the protective response is provided against Marek's Disease Virus MDV, NDV and/or IBDV. 
Marek's Disease Virus - MDV), pri čemu taj postupak obuhvaća najmanje jednu primjenu pripravka ili cjepiva.
is —C(O)phenyl or —C(O) heteroaryl; wherein said heteroaryl is pyridinyl, furanyl or thienyl; wherein heteroaryl is independently optionally substituted with a member selected from the group consisting of halogen, methyl, -amino, —NHMe, NMe2 and hydroxymethyl; 
R'* je -C(O)fenil ili -C(O) heteroaril; gdje je taj heteroaril piridinil, furanil ili tienil; heteroaril je nezavisno po izboru supstituiran članom izabranim iz skupine koja obuhvaća halogen, metil, -amino, -NHMe, NMe, i hidroksimetil.
The drug may also alter the pain threshold (threshold of afferent nerve endings to noxious stimuli). 
Lijek može također izmijeniti prag boli (prag osjetljivosti aferentnih živčanih završetaka na štetne podražaje).
homogenous distribution of different components; 
- < ravnomjerna raspodjela različitih sastojaka;
Sphingosine-1 phosphate receptor agonists, such as fingolimod (Novartis) 
agonista receptora sfingosin-1 fosfata kao što je fingolimod (Novartis);
said pH buffering agent is 10 mM histidine and the pH is 7.0; said bulking agent is 4% w/v mannitol; said stabilizing agent is 2% w/v sucrose; and said surfactant is 0.01% w/v polysorbate-20; or 
navedeni pH puferski agens je 10 mM histidin i pH je 7.0; navedeno sredstvo za dopunjavanje je 4% w/v manitol; navedeni stabilizator je 2 % w/v saharoza; i navedena površinski aktivna materija je 0.01 % w/v polisorbat-20; ili
The drive gear (12) passes through the center (21) of the housing and joins the mouthpiece cover (2) at two points. 
Uređaj za inhaliranje prema zahtjevu 5, naznačen time da je područje površine završetka pogonskog zupčanika (12a) koji je spojen na poklopac nastavka za usta (2) u rasponu od 32-90 mm'.
The solid pharmaceutical composition of embodiment 1, further comprising an excipient selected from the group consisting of mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, cyclodextrin, and combinations thereof. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 1, koja nadalje sadrži ekscipijens koji se bira iz skupine koju čine manitol, ksilitol, sorbitol, maltol, maltitol, laktoza, saharoza, maltoza, ciklodekstrin, i njihove kombinacije.
n is 0, 1, 2 or 3; and/or pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof. 
N(CHs),, imidazolil, iili N-morfolinil; i/ili farmaceutski prihvatljive soli, solvati, stereoizomeri i/ili hidrati ovog spoja.
Examples of such conditions include the use of phosphorus-based dehydrating agents such as phosphorus halides or phosphorus oxyhalides, e.g. POCl3 and PCl5. 
Primjeri takvih stanja uključuju uporabu sredstava za dehidriranje na bazi fosfora poput fosfor halida ili fosfor oksihalida, na primjer POCI; i PCls.
Thus, A2A receptor antagonists show great potential as future drugs for long-term medication of PD patients, since they do not only reverse the motor impairment but also can slow down or stop the progress of the disease by promoting cell survival. 
Prema tome, antagonisti A,,-receptora pokazuju veliki potencijal kao lijekovi budućnosti za dugotrajno liječenje pacijenata koji boluju od Parkinsonove bolesti, budući da motorička oštećenja koja se javljaju su reverzibilnog karaktera, već i pokazuju sposobnost da uspore ili zaustave razvoj bolesti promičući dulji život stanice.
R'4 is a hydrogen atom or a (C1-C6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group; 
pri čemu: R'4 je vodikov atom ili (C1-C6)alkil ili aril skupina, navedene alkil i aril skupine su proizvoljno supstituirane s atomom halogena ili NH2 ili OH skupinom;
Compound of formula (I) as defined in any one of the preceding claims 1 to 7 for use in the treatment of diseases based on the expression of CX3CR1 and p40 selected from the group comprising diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, myocardial infarction, angina, lupus erythematosus, psoriasis, and type II diabetes. 
Uporaba prema zahtjevu 22, naznačena time, da su navedene bolesti koje su bazirane na ekspresiji CX3CR1, odabrane iz skupine koju čine: reumatoidni artritis, lupus nefritis, dijabetska nefropatija, Chronova bolest, ulcerativni kolitis, koronarni poremećaji, restenoza, ateroskleroza, infarkt miokarda i angina.
distilling said crude product to produce an overhead stream and a bottom stream, the overhead stream comprising 1,1,1,3-tetrachloropropane and unreacted carbon tetrachloride, and the bottom stream comprising 1,1,1,3-tetrachloropropane; 
(li) destilaciju tog sirovog proizvoda radi dobivanja gornjeg i donjeg protoka, gornji protok sadrži 1,1,1,3- tetrakloropropan i neizreagirani ugljik tetraklorid, i donji protok sadrži 1,1,1,3-tetrakloropropan;
The injection of claim 3, wherein the injection is consisted of (by weight): 1∼20 parts of 5a-androstane-3B,5,6B-triol, 40∼500 parts of hydroxypropyl-B-cyclodextrin, 1∼100 parts of an isotonic adjusting agent, 0∼200 parts of a freeze drying filler, and 0∼2000 parts of a solvent. 
Injekcija prema patentnom zahtjevu 3, gdje se injekcija sastoji od (po masi): 1-20 dijelova 5a-androstan-3B,5,6f- triola, 40-500 dijelova hidroksipropil-B-ciklodekstrina, 1100 dijelova izotoničnog sredstva za prilagodbu, 0-200 dijelova punila za ledeno sušenje, te 0-2000 dijelova otapala.
A compound having the formula selected from: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising: the compound according to claim 1; and 
Spoj, naznačen time, da ima formulu odabranu od: x Prve, po ž Ž Zeta Ž so koa ida že KA £ ili njegova farmaceutski prihvatljiva sol.
The method of any one of items 1-13, wherein the composition comprising nanoparticles comprising a taxane and albumin is administered parenterally. 
Pripravak ili kombinacija za uporabu prema bilo kojem od zahtjeva 1-9, gdje se pripravak koji sadrži nanočestice s taksanom i albuminom primjenjuje parenteralno, poželjno intravenski, intraarterijski, intrahepatalno ili intraportalno.
The pharmaceutical composition according to claim 19, wherein said composition is in the form of a cream, gel, suspension, ointment, paste, dispersion or emulsion. 
Farmaceutski pripravak prema patentnom zahtjevu 2 u obliku tablete, kapsule, praška, pilule, suspenzije, emulzije, kreme, gela, masti, losiona, disperzije ili paste.
In one embodiment, the fragments are analyzed by sequencing a plurality of nucleic acid molecules from the biological sample obtained from the pregnant female. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što statistička raspodjela ovisi o frakcionalnoj koncentraciji molekula nukleinske kiseline iz biološkog uzorka dobivenih iz fetusa.
the pharmaceutical composition according to (17), for treating and/or preventing pain; 
Farmaceutski pripravak prema zahtjevu 7, za uporabu u liječenju i/ili prevenciji boli.
A compound for use in a method for the prevention and/or treatment of at least one disease or disorder selected from the group comprising eye diseases; airway diseases; cardiovascular and vascular diseases; inflammatory diseases; neurological and CNS disorders: proliferative diseases;; bone diseases; benign prostatic hyperplasia; transplant rejection; spasm; hypertension; chronic obstructive bladder disease; and allergy; said method comprising administering to a subject in need thereof a therapeutic effective amount of a compound as defined in claims 1 to 6, or a composition as defined in claim 8. 
Spoj za upotrebu u postupku za prevenciju i/ili liječenje najmanje jedne bolesti ili poremećaja odabrano iz skupine koja sadrži bolesti oka; bolesti dišnih puteva; kardiovaskularne i vaskularne bolesti; upalne bolesti; neurološke poremećaje i poremećaje CNS-a: proliferativne bolesti; bolesti kostiju; benignu hiperplaziju prostate; odbacivanje transplantanta; spazam; hipertenziju; kroničnu opstruktivnu bolest mjehura; i alergiju; pri čemu navedeni postupak sadrži primjenu na pojedinca kod kojeg postoji potreba za tim terapeutski učinkovite količine spoja kao što je definirano u patentnim zahtjevima 1 do 6, ili pripravka definiranog u patentnom zahtjevu 8.
Unlike known solutions, each scraping device 7 of mixing member 1 is substantially defined by a preferably, though not necessarily, plastic or metal scraper 8, which is hinged to the body of longitudinal blade 4 so as to project from and oscillate about an axis of rotation B locally substantially parallel to outer lateral edge 4 b of longitudinal blade 4 and/or to longitudinal axis A of mixing member 1, and extends in a direction substantially tangent to the circular path traveled by outer lateral edge 4 b as mixing member 1 rotates about longitudinal axis A, while remaining locally substantially perpendicular to axis B. 
Za razliku od poznatih rješenja, svako strugalo 7 članka za miješanje 1 je u biti definirano pogodnim, premda ne i nužnim, plastičnim ili metalnim strugačem 8, koji je obješen na tijelo uzdužne lopatice 4 tako da strši i oscilira oko osi rotacije B lokalno u biti paralelne vanjskom bočnom bridu 4b uzdužne lopatice 4 i/ili uzdužne osi A članka za miješanje 1 i pruža se u smjeru u biti tangencijalnom na kružni put kojim se kreće vanjski bočni brid 4b, kako članak za miješanje 1 rotira oko uzdužne osi A, dok u biti ostaje lokalno okomit na os B.
Use of glyoxal for removal of calcium from crude oil or its blends containing calcium naphthenate at low pH of 3 to 4, and also at high pH of 5 or more of the wash water for the desalter used in the crude oil processing systems, characterized in that crude oil or its blends containing calcium naphthenate is treated with glyoxal. 
Upotreba glioksala za uklanjanje kalcija iz sirove nafte ili njezinih mješavina koje sadrže kalcij naftenat pri niskom PH od 3 do 4, 1 također pri visokom pH od 5 ili više vode za ispiranje koja se koristi u sustavima prerade sirove nafte, naznačena time što se sirova nafta ili njezine mješavine koje sadrže kalcij naftenat tretiraju s glioksalom.
The adenosine deaminase for use of claim 1, wherein the adenosine deaminase is adenosine deaminase purified from a bovine source or is a recombinant adenosine deaminase. 
Adenozin-deaminaza, namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što je adenozin-deaminaza adenozin-deaminaza pročišćena iz goveđeg izvora ili je rekombinantna adenozin-deaminaza.
Use of the B cell of claim 12 to make a hybridoma that expresses a light chain derived from a hVλ a hJλ and a mouse Cλ gene, wherein the hybridoma is from, or obtainable from, the mouse of any one of claims 1 to 10, wherein the cell comprises a rearranged human Vλ and a rearranged human Jλ gene segment, and a deletion of a first Vλ-Jλ-Cλ gene cluster of said endogenous mouse λ light chain allele and replacement, in whole or in part, of the Vλ-Jλ gene segments of the second Vλ-Jλ-Cλ gene cluster of said allele with said human Vλ and Jλ gene segments which are operably linked to an intact mouse Cλ constant region gene of said second Vλ-Jλ-Cλ gene cluster and wherein the endogenous enhancers Enh 2.4, mouse lambda 3' enhancer (Enh) and Enh 3.1 are maintained intact in said λ light chain allele. 
Hibridom koji sadrži preuređenu sekvencu gena imunoglobulinskog lakog lanca dobivenu iz miša prema patentnom zahtjevu 1, preuređenu sekvencu koja sadrži segment gena hVλ, segment gena hJλ i mišji gen Ck na lokusu endogenog mišjeg imunoglobulinskog lakog lanca k, naznačen time, što se na spomenutom lokusu održava element intronskog pojačivača k uzvodno od gena Ck (označen kao Eki) i pojačivač 3' k nizvodno od gena Ck (označen kao Ek3'), pri čemu hibridom izražava antitijelo koje sadrži laki lanac koji sadrži preuređenu humanu sekvencu Vλ-Jλ i mišju sekvencu Ck.
A modified serpin according to any one of clauses 1 to 25 wherein the mutations in the RCL of the modified serpin consist of mutations at positions P1', P2 and P4. 
Modificirani serpin prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se mutacije u RCL-petlji od modificiranog serpina, sastoje od mutacija na pozicijama P1' i P2; pozicijama P1', P2 i P1; pozicijama P1', P2 i P4; ili pozicijama P1', P2, P4 1 P1.
The humanized CD37-specific binding protein of any of claims 1-8 or the composition of claim 10 for use in claim 19, wherein the second agent is a chemotherapeutic agent, and wherein the chemotherapeutic agent is fludarabine or chlorambucil. 
Humanizirani CD37-specifični vezni protein iz bilo kojeg od patentnih zahtjeva 1 do 8, ili sastav iz patentnog zahtjeva 10, za uporabu u patentnom zahtjevu 19, pri čemu je drugi agens kemoterapijski agens, i pri čemu je kemoterapijski agens fludarabin ili klorambucil.
A method of treating an alcohol-related disease, comprising: administering an antagonist of the serotonin receptor 5-HT3 to a patient known to have the LL genotype of functional polymorphism serotonin transporter-linked polymorphic region 5-HTTLPR of the serotonin transporter gene SLC6A4 and known to have the TT genotype of the single nucleotide polymorphism rs1042173 of the serotonin transporter gene SLC6A4. The method of claim 1, wherein the 5-HT3 antagonist is ondansetron. 
Antagonist receptora serotonina 5-HT3 za uporabu u liječenju alkoholizma u bolesnika u skladu s patentnim zahtjevom 7, pri čemu je biološki uzorak bolesnika prethodno bio ispitan analizom koja je u mogućnosti pokazati da bolesnik ima LL genotip funkcionalnog polimorfizma polimorfne regije 5-HTTLPR povezane s prijenosnikom serotonina gena za prijenosnik serotonina SLC6A4 1 pri čemu je biološki uzorak bolesnika prethodno bio ispitan analizom koja je u mogućnosti pokazati da bolesnik ima TT genotip polimorfizma jednog nukleotida rs 1042173 gena za prijenosnik serotonina SLC6A4.
The amount of water in the obtained tablets was determined to be 5.5 % by the Karl Fischer method which was performed according to Ph. Eur. 
Količina vode u dobivenim tabletama određena je Karl Fischerovom metodom i iznosila je 5,5 % težine.
Chemotherapeutic agents which can be used include: alkylating agents, intercalators, antimetabolite, enzyme inhibitors and blockers and spindle poisons (for example alkylsulfonate, ethylimine, nitrosomonas (N. ureae), nitrogen mustard derivatives, folic acid analogs, purine analogs, pyrimidine analogs, podophyllin derivatives, taxane, vincaalcaloide, anthracycline, other cytostatic antibiotics, platinum compounds, campthotecin derivatives, different hormones, growth factors, interferons or interleukins), otherwise the chemotherapeutic agents described in “Onkologie 2004/05”, authors Preiss, Dornhoff, Hagmann, Schmieder, published by Zuckschwerdtverlag, at pp. 
Derivati peptida GLP-1 u skladu s prethodnim patentnim zahtjevima, naznačeni time što kemoterapeutik se osobito bira iz skupine koju čine alkilsulfonati, etilimini, nitrozoharska sredstva, derivati dušičnog iperita, analozi folne kiseline, analozi purina, analozi pirimidina, derivati podofilina, taksani, Vinca alkaloidi, antraciklini, drugi citostatski antibiotici, spojevi platine, derivati kamptotecina, hormoni, čimbenici rasta, interferoni ili interleukini, ili tvari citostatskog ili citotoksičnog djelovanja.
determining a driver profile from the one or more selected events; characterising the driving behaviour of the driver on a basis of the driver profile; and 
utvrđivanje (4) profila vozača (6) iz odabranog događaja; i određivanje (9) ponašanja u vožnji vozača temeljem vozačevog profila (6).
No. 6,262,871 refers to an electronic circuit for automatically testing a GFCI; an important feature of this invention is that it must be coupled with an already realized GFCI or it must comprise the essential components thereof. 
Patent US 6 262 871 opisuje elektronički sklop za automatsko testiranje GFCI; važna stvar ovog izuma je to što mora biti povezan s već postojećim GFCI, ili mora sadržati njegove osnovne komponente.
Typical compositions for nasal delivery include those mentioned above for inhalation and further include non-pressurized compositions in the form of a solution or suspension in an inert vehicle such as water optionally in combination with conventional excipients such as buffers, anti-microbials, mucoadhesive agents, tonicity modifying agents and viscosity modifying agents which may be administered by nasal pump. 
Tipični pripravci za nazalnu isporuku uključuju prethodno navedene pripravke za inhalaciju te dodatno pripravke za netlačnu isporuku u obliku otopine ili suspenzije u inertnom vehikulu poput vode, po izboru u kombinaciji s uobičajenim ekscipijensima poput pufera, antimikrobnih sredstava, mukoadhesivnih sredstava, sredstava za promjenu tonusa i sredstvima za promjenu viskoznosti, koje se daju putem nazalne pumpice.
The organic portion is separated, dried (Na2SO4) and concentrated in vacuo. 
Organski dio se odvoji, osuši(Na25Oy4) i koncentrira u vakuumu.
Secukinumab for use in treating psoriasis, characterized in that 150 mg or 300 mg of secukinumab is to be administered to a patient in need thereof by subcutaneous injection, with initial dosing at weeks 0, 1, 2, 3, and 4, followed by maintenance dosing of 150 mg or 300 mg secukinumab every four weeks, wherein the patient is an adult patient who is a candidate for systemic therapy. 
Secukinumab, naznačen time, da se upotrebljava u liječenju psorijaze, pri čemu se pacijentu kojemu je to potrebno, treba davati pet tjednih doza od 150 mg do 300 mg secukinumaba; te time, da nakon toga pacijentu treba davati od 150 mg do 300 mg secukinumaba mjesečno.
Preferably, step (f′)(iii) comprises the steps: 
(2) Korak spajanja (e) sadrži korake:
Underground tank (tunnel-tank) in the open (sunken or above-ground) according to claim 4, characterized by the fact that the insertion of the monitoring pipe is facilitated by the creation of specific pockets, of suitable size, created in the static structure or in the static facing of the tank. 
Spremnik u skladu s patentnim zahtjevom 1, naznačen time, da je umetanje cjevčice za nadzor olakšano predviđenim posebnih džepova prikladne veličine koji su izrađeni u statičnoj konstrukciji (3) ili u statičnoj oplati spremnika.
The apparatus of claim 1, wherein, when the intra prediction mode is a planar mode, the reference pixel generator generates the prediction block using a corner reference pixel, a left reference pixel and an upper reference pixel. 
Uređaj iz zahtjeva 1, pri čemu se, kada je intrapredikcijski režim planarni režim, jedinica intrapredikcijskog predviđanja (150) generira prediskcijski blok pomoću kutnog referentnog piksela, lijevog referentnog piksela i gornjeg referentnog piksela.
cooling the suspension to about −10° C.; 
(i) hlađenje suspenzije na oko -10%C;
(a-iii) adding the glyoxalated copolymer composition and cellulose fibers to an aqueous solution; and (a-iv) reacting in an aqueous reaction medium comprising cellulose fibers a dry weight ratio of glyoxal:cationic copolymer ranging from 5 to 40 glyoxal to 95 to 60 cationic copolymer to form the glyoxalated copolymer, 
(a-iti) dodavanje sastava glioksaliranog kopolimera i vlakana celuloze u vodenu otopinu; te (a-iv) reakcija u vodenom reakcijskom mediju koja sadrži vlakna celuloze u suhom omjeru masa glioksal: kationski kopolimer u rasponu od 5 do 40 glioksal do 95 do 60 kationski kopolimer kako bi se dobio glioksalirani kopolimer, gdje je glioksalirani kopolimer 0,25 do 4 masena % zasnovano na ukupnoj masi vodenog reakcijskog medija.
1 shows the arrangement 1 according to a first embodiment as an exploded drawing, namely with the upper part 3 lifted off. 
Slika 1 prikazuje napravu 1 prema prvoj izvedbi u rastavljenom obliku, naime s podignutim gornjim dijelom 3.
separating the solvent layers; and extracting the compound of formula (XIV), or a boronic acid anhydride thereof, into an organic solvent 
(ili) odvajanja slojeva otapala; i (iv) ekstrakcije spoja formule (XIV) ili njegovog anhidrida organoborne kiseline, u organsko otapalo.
Compound (a) is dissolved in acetonitrile (0.1M) and treated with 2 eq of 2-bromo-2-methyl-propionic tert-butyl ester and 2.5 eq of cesium carbonate. 
Spoj (a) otopi se u acetonitrilu (0,1 M), te obradi s 2 ekv. fert-butilnog estera 2-brom-2-metilpropionske kiseline i 2,5 ekv. cezijevog karbonata.
The method according to claim 8, wherein the single portion of chewing gum contains said additional zinc salt in such amounts as to supply 0.1 to 10 mg of zinc. 
Žvakaća guma prema patentnom zahtjevu 13, naznačeno time da rečena dodatna cinkova sol u jednom obroku žvakaće gume opskrbljuje s 0.1 do 10 mg cinka.